AxoGen, Inc. (NASDAQ:AXGN) hit a new 52-week high during trading on Monday . The company traded as high as $18.90 and last traded at $18.90, with a volume of 371,590 shares changing hands. The stock had previously closed at $18.50.

A number of equities research analysts recently commented on the company. Roth Capital reiterated a “buy” rating and issued a $21.00 target price (up previously from $18.00) on shares of AxoGen in a research report on Tuesday, September 12th. BidaskClub lowered AxoGen from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. Cantor Fitzgerald reiterated a “buy” rating and issued a $18.00 target price on shares of AxoGen in a research report on Monday, August 21st. Leerink Swann assumed coverage on AxoGen in a research report on Monday, July 31st. They issued an “outperform” rating and a $22.00 target price on the stock. Finally, ValuEngine upgraded AxoGen from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $17.20.

The stock’s market cap is $619.93 million. The company’s 50 day moving average price is $16.58 and its 200 day moving average price is $14.19.

AxoGen (NASDAQ:AXGN) last released its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. The firm had revenue of $15.20 million for the quarter, compared to the consensus estimate of $14.40 million. AxoGen had a negative return on equity of 114.64% and a negative net margin of 27.50%. The firm’s quarterly revenue was up 46.2% compared to the same quarter last year. During the same quarter last year, the business posted ($0.09) EPS. Equities research analysts expect that AxoGen, Inc. will post ($0.31) EPS for the current year.

In related news, Director Robert James Rudelius sold 16,143 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $18.00, for a total transaction of $290,574.00. Following the transaction, the director now owns 43,273 shares in the company, valued at approximately $778,914. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 9.33% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Parametric Portfolio Associates LLC grew its stake in shares of AxoGen by 0.9% in the 1st quarter. Parametric Portfolio Associates LLC now owns 10,843 shares of the medical equipment provider’s stock valued at $113,000 after purchasing an additional 93 shares during the last quarter. Nationwide Fund Advisors grew its stake in shares of AxoGen by 5.5% in the 2nd quarter. Nationwide Fund Advisors now owns 14,874 shares of the medical equipment provider’s stock valued at $249,000 after purchasing an additional 774 shares during the last quarter. Bank of America Corp DE grew its stake in shares of AxoGen by 8.7% in the 1st quarter. Bank of America Corp DE now owns 10,183 shares of the medical equipment provider’s stock valued at $106,000 after purchasing an additional 814 shares during the last quarter. American International Group Inc. grew its stake in shares of AxoGen by 7.7% in the 1st quarter. American International Group Inc. now owns 14,941 shares of the medical equipment provider’s stock valued at $156,000 after purchasing an additional 1,068 shares during the last quarter. Finally, UBS Group AG grew its stake in shares of AxoGen by 8.3% in the 1st quarter. UBS Group AG now owns 16,141 shares of the medical equipment provider’s stock valued at $169,000 after purchasing an additional 1,234 shares during the last quarter. Hedge funds and other institutional investors own 66.77% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “AxoGen, Inc. (AXGN) Hits New 12-Month High at $18.90” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/09/20/axogen-inc-axgn-hits-new-12-month-high-at-18-90.html.

AxoGen Company Profile

AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.